Recently, China’s national basic medical insurance program began to reimburse hospitals with DRG and gradually promoted it nationwide. The reform of medical insurance payment methods can better control the unreasonable increase in medical service costs, but it may also have adverse effects on the development of new medical technologies. Based on the analysis the reasons for the adverse impact, this article introduces the main practice of the current compensation payment system for new medical technologies. This paper classifies payment mechanisms for new technology in different countries into additional payments and separate payments based on whether or not they are included in the DRG payment system. Classical practice at home and abroad is introduced, including American New Technology Add-on Payment, German New Diagnostic and Treatment Methods, Japan C1 and C2 for medical devices, additional payment in Zhejiang province and excluded payment in Beijing. Application criteria should be set to establish a dynamic adjustment mechanism, and effective communication should be promoted between hospitals and medical insurance agencies to develop site-specific policies. Also, we should measure the cost of new technology reasonably and improve the DRG/DIP payment system, develop commercial medical insurance for new technologies and establish a multi-level medical security system.
Key words
DRG /
new technology payment /
additional payment /
separate payment
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Bhattachary J, Hyde T, Tu P.健康经济学[M].桂林:广西师范大学,2019:254-271.
[2] HERNANDEZ J, MACHACZ S F, ROBINSON J C.US Hospital Payment Adjustments For Innovative Technology Lag Behind Those In Germany, France, And Japan[J]. Health Affairs, 2015,34(2):261-270.
[3] DARON A,JOSHUA L.Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry[J]. The Quarterly Journal of Economics, 2004, 119.
[4] RAKE B.Determinants of pharmaceutical innovation: The role of technological opportunities revisited[J]. Jena Economic Research Papers, 2012.
[5] BLUME-KOHOUT M.E., SOOD N.The Impact of Medicare Part D on Pharmaceutical R&D[J].NBER Working Papers,2008.
[6] 丛鹂萱,王海银,金春林.美国创新医疗技术支付经验及启示[J].卫生经济研究,2019,36(07):10-13.
[7] 吴晶,董心月,赵博雅.美国DRG下高值创新医疗技术的支付政策及启示[J].中国医疗保险,2022(06):118-124.
[8] MACCARIELLA-HAFEY P.Part 4: New ICD-10 Codes and IPPS Changes for 2023[EB/OL].(2022-09-26)[2023-03-05].https://hiacode.com/blog/ntap-2023.
[9] MACCARIELLA-HAFEY P. Part 4:New2022 Technology Add-On Payments (NTAP)[EB/OL].(2021-09-22)[2023-03-05].https://hiacode.com/blog/education/technology-add-on-payments.
[10] 常峰,纪美艳,路云.德国的G-DRG医保支付制度及对我国的启示[J].中国卫生经济,2016,35(06):92-96.
[11] 雷璐倩,张伶俐,颜建周,等.德国医疗保险支付方式改革及对我国的启示[J].中国卫生资源,2020,23(02):176-181.
[12] 李伟,任雨青,丁锦希,等.德国DRG医院偿付系统中创新产品支付模式分析[J].中国医院,2021,25(12):40-42.
[13] 郎婧婧,于丽华.典型国家DRG体系下新技术支付政策分析及启示[J].中国卫生质量管理,2022,29(04):21-24.
[14] 赵思雨,马艳良,王茹.诊断相关分组下的除外机制探讨[J].中国社会保障,2020(12):86-87.
[15] InEK. Aufstellung der Informationen nach § 6 Abs. 2 KHEntgG für 2023[EB/OL].(2023-01-31)[2023-03-05].https://www.g-drg.de/ag-drg-system-2023/neue-untersuchungs-und-behandlungsmethoden-nub/aufstellung-der-informationen-nach-6-abs.-2-khentgg-fuer-2023.
[16] 浙江省医保局.浙江省基本医疗保险DRGs点数付费评价项目[EB/OL].(2021-12-01)[2023-03-05].http://ybj.zj.gov.cn/art/2021/12/1/art_1229226156_4814539.html.
[17] 刘心怡,张璐莹,尚春晓,等.DRG付费下创新药品支付的国际经验与启示[J].世界临床药物,2021,42(07):547-550.
[18] TAMURA M, NAKANO S, SUGAHARA T.Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?[J].Int J Health Plann Mgmt. 2019,34:583-593
[19] Ministry of Health, Labour and Welfare. Statistics of production by pharmaceutical industry[EB/OL].(2023-01-17)[2023-03-05].https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000138360.html.
[20] 玄律,程超,郑杰,等.北京市DRG付费改革实践及DRG付费国家试点技术方案特点分析[J].中国医疗保险,2020(09):36-39.
[21] 北京市医疗保险事务管理中心.关于印发CHS-DRG付费新药新技术除外支付管理办法的通知(试行)[EB/OL].(2022-07-13)[2023-03-05].http://ybj.beijing.gov.cn/tzgg2022/202207/t20220713_2798069.html.
[22] 肖力玮,吕国营.新时代基本医疗保险依然必须坚守“保基本”[J].中国医疗保险,2019(04):18-20.
